Maxwell R. Lloyd

Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors

Viktor A. Adalsteinsson, Gavin Ha, Samuel S. Freeman et al. · Nature Communications · 2017 · 1.1K citations · Full text

Medicine, Molecular Biology, Oncology +17

The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer

Seth A. Wander, Ofir Cohen, Xueqian Gong et al. · Cancer Discovery · 2020 · 433 citations · Full text

Medicine, Cancer Biology, Oncology +17

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

Adrienne G. Waks, Ofir Cohen, Bose Kochupurakkal et al. · Annals of Oncology · 2020 · 156 citations · Full text

Medicine, Cancer Biology, Oncology +17

Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer

Daniel G. Stover, Carlos R. Gil Del Alcazar, Jane Brock et al. · npj Breast Cancer · 2018 · 150 citations · Full text

Medicine, Oncology, Pharmacology +16

Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience

Seth A. Wander, Hyo S. Han, Mark L. Zangardi et al. · Journal of the National Comprehensive Cancer Network · 2021 · 85 citations

Medicine, Oncology, Pharmacology +16